St. Jude buys Nanostim for $123.5M

Candace Stuart | | Cardiovascular Business | Heart Rhythm

St. Jude Medical acquired Nanostim, a developer of miniaturized leadless pacemakers, for $123.5 million after a two-year partnership with the company.

Nanostim’s leadless pacemaker received CE Mark in Europe and conditional approval from the FDA to test the product. The small leadless pacemaker is delivered via a catheter in the femoral vein to the heart. The device is retrievable to replace the battery or reposition it during delivery.

The agreement includes a $65 million cash payment to Milpitas, Calif.-based Nanostim, contingent on meeting defined milestones. St. Jude is based in St. Paul, Minn.

Candace Stuart, Contributor

Related Content

Eko Health’s AI platform for digital stethoscopes granted new CPT code
Predicting sudden cardiac death after a heart attack may be impossible—for now
Concomitant ablation surgery during heart operations boosts long-term survival
Johnson & Johnson MedTech gains FDA approval for Varipulse PFA system
Boston Scientific agrees to acquire AFib ablation company
Heart Rhythm Society launches new group focused on EP advocacy

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Design by Adaptive Theme
Trimed Popup
Trimed Popup